| scholarly article | Q13442814 |
| P50 | author | R. Daniel Bonfil | Q67488266 |
| M. Katie Conley-LaComb | Q93138508 | ||
| Hyeong-Reh Choi Kim | Q116796852 | ||
| P2093 | author name string | Wei Huang | |
| Michael L Cher | |||
| Shihua Wang | |||
| Yong Q Chen | |||
| Young Suk Jung | |||
| Rafael Fridman | |||
| Dongping Shi | |||
| Abdo Najy | |||
| P2860 | cites work | The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate | Q24317714 |
| Platelet-derived growth factor D is activated by urokinase plasminogen activator in prostate carcinoma cells | Q24531982 | ||
| Modulation of prostate cancer genetic risk by omega-3 and omega-6 fatty acids | Q24674656 | ||
| PtdIns(3,4,5)P(3)-dependent and -independent roles for PTEN in the control of cell migration | Q24677034 | ||
| Cancer statistics, 2010 | Q27860525 | ||
| PDGF-D, a new protease-activated growth factor | Q28186722 | ||
| Essential role for nuclear PTEN in maintaining chromosomal integrity | Q28513781 | ||
| Reduction of Akt2 inhibits migration and invasion of glioma cells | Q28572665 | ||
| Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer | Q28590839 | ||
| TMEFF2 is a PDGF-AA binding protein with methylation-associated gene silencing in multiple cancer types including glioma | Q28740616 | ||
| The LKB1-AMPK pathway: metabolism and growth control in tumour suppression | Q29617506 | ||
| PTEN can inhibit in vitro organotypic and in vivo orthotopic invasion of human bladder cancer cells even in the absence of its lipid phosphatase activity | Q30434033 | ||
| The multiple roles of PTEN in tumor suppression | Q33849727 | ||
| Diminished matrix metalloproteinase 2 (MMP-2) in ectomesenchyme-derived tissues of the Patch mutant mouse: regulation of MMP-2 by PDGF and effects on mesenchymal cell migration. | Q52175351 | ||
| Gene expression correlates of clinical prostate cancer behavior | Q60156349 | ||
| Immunohistochemistry analysis of platelet-derived growth factor A and B chains and platelet-derived growth factor alpha and beta receptor expression in benign prostatic hyperplasias and Gleason-graded human prostate adenocarcinomas | Q71652817 | ||
| Platelet-derived growth factor A and B chains and the alpha and beta receptors in prostatic intraepithelial neoplasia | Q71740261 | ||
| Extracellular calcium and platelet-derived growth factor promote receptor-mediated chemotaxis in osteoblasts through different signaling pathways | Q73248309 | ||
| Impaired vascular invasion of Cbfa1-deficient cartilage engrafted in the spleen | Q74407916 | ||
| PTEN loss inhibits CHK1 to cause double stranded-DNA breaks in cells | Q81877328 | ||
| PDGF-D is a specific, protease-activated ligand for the PDGF beta-receptor | Q33945092 | ||
| Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. | Q33997854 | ||
| Induction and regulation of epithelial-mesenchymal transitions | Q34047215 | ||
| Complement components C1r/C1s, bone morphogenic protein 1 and Xenopus laevis developmentally regulated protein UVS.2 share common repeats | Q34104733 | ||
| A potential oncogenic activity of platelet-derived growth factor d in prostate cancer progression | Q34224640 | ||
| A novel signaling axis of matriptase/PDGF-D/ß-PDGFR in human prostate cancer | Q34683885 | ||
| Platelet-derived growth factor signaling and human cancer | Q35051106 | ||
| Practical management of patients with chronic myeloid leukemia receiving imatinib | Q35095956 | ||
| Smart drugs in prostate cancer | Q35604827 | ||
| Indications for imatinib mesylate therapy and clinical management | Q35787974 | ||
| Tyrosine kinases expressed in vivo by human prostate cancer bone marrow metastases and loss of the type 1 insulin-like growth factor receptor | Q35788293 | ||
| Differential nuclear and cytoplasmic expression of PTEN in normal thyroid tissue, and benign and malignant epithelial thyroid tumors | Q35810225 | ||
| Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression | Q36067596 | ||
| Inactivation of PTEN is associated with increased angiogenesis and VEGF overexpression in gastric cancer | Q36178164 | ||
| Shc and FAK differentially regulate cell motility and directionality modulated by PTEN. | Q36301565 | ||
| Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 3' kinase/AKT pathways | Q36313178 | ||
| Characterization of adult prostatic progenitor/stem cells exhibiting self-renewal and multilineage differentiation | Q36713740 | ||
| Tenets of PTEN tumor suppression | Q37154214 | ||
| AMPK: a key regulator of energy balance in the single cell and the whole organism. | Q37249357 | ||
| PTEN and the PI3-kinase pathway in cancer | Q37259680 | ||
| AMP-activated protein kinase promotes human prostate cancer cell growth and survival | Q37415957 | ||
| A multi-institutional phase ii study of SU101, a platelet-derived growth factor receptor inhibitor, for patients with hormone-refractory prostate cancer | Q38461620 | ||
| AMPK-mediated autophagy is a survival mechanism in androgen-dependent prostate cancer cells subjected to androgen deprivation and hypoxia | Q39545841 | ||
| Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases | Q39644572 | ||
| Mutation and expression analysis of the putative prostate tumour-suppressor gene PTEN | Q39711051 | ||
| Inactivation of AMPK alters gene expression and promotes growth of prostate cancer cells. | Q39863992 | ||
| The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. | Q40021818 | ||
| Critical roles of AMP-activated protein kinase in the carcinogenic metal-induced expression of VEGF and HIF-1 proteins in DU145 prostate carcinoma | Q40282981 | ||
| AMP-dependent protein kinase alpha 2 isoform promotes hypoxia-induced VEGF expression in human glioblastoma | Q40308352 | ||
| Glucose deprivation increases mRNA stability of vascular endothelial growth factor through activation of AMP-activated protein kinase in DU145 prostate carcinoma. | Q40473451 | ||
| Antitumor effects of thalidomide analogs in human prostate cancer xenografts implanted in immunodeficient mice | Q40541637 | ||
| The protein kinase Akt induces epithelial mesenchymal transition and promotes enhanced motility and invasiveness of squamous cell carcinoma lines. | Q40590650 | ||
| Platelet-derived growth factor BB secreted from osteoclasts acts as an osteoblastogenesis inhibitory factor | Q40754782 | ||
| Transforming growth factor-beta1-induced proliferation of the prostate cancer cell line, TSU-Pr1: the role of platelet-derived growth factor | Q40937791 | ||
| Nuclear PTEN-mediated growth suppression is independent of Akt down-regulation | Q42076186 | ||
| Culture of mouse prostatic epithelial cells from genetically engineered mice | Q42471864 | ||
| The uPA/uPAR system regulates the bioavailability of PDGF-DD: implications for tumour growth | Q42806622 | ||
| PTEN inhibits cell proliferation and induces apoptosis by downregulating cell surface IGF-IR expression in prostate cancer cells | Q44737517 | ||
| Differential growth factor control of bone formation through osteoprogenitor differentiation | Q44788381 | ||
| Simultaneous blockade of platelet-derived growth factor-receptor and epidermal growth factor-receptor signaling and systemic administration of paclitaxel as therapy for human prostate cancer metastasis in bone of nude mice | Q44942702 | ||
| Differential regulation of platelet-derived growth factor stimulated migration and proliferation in osteoblastic cells | Q45231176 | ||
| Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases | Q46972241 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | prostate cancer | Q181257 |
| P304 | page(s) | 1017-1027 | |
| P577 | publication date | 2011-12-28 | |
| P1433 | published in | The American Journal of Pathology | Q4744259 |
| P1476 | title | PTEN regulates PDGF ligand switch for β-PDGFR signaling in prostate cancer | |
| P478 | volume | 180 |
| Q37035984 | A critical role of the PTEN/PDGF signaling network for the regulation of radiosensitivity in adenocarcinoma of the prostate |
| Q38673563 | DNA methylation-based chromatin compartments and ChIP-seq profiles reveal transcriptional drivers of prostate carcinogenesis |
| Q37593021 | Differential tumorigenic potential and matriptase activation between PDGF B versus PDGF D in prostate cancer |
| Q26859634 | Emerging roles of PDGF-D in EMT progression during tumorigenesis |
| Q46823306 | Functional regulation of adipose-derived stem cells by PDGF-D. |
| Q41967756 | High expression of PDGFR-β in prostate cancer stroma is independently associated with clinical and biochemical prostate cancer recurrence |
| Q97681363 | Identification of candidate miRNAs in early-onset and late-onset prostate cancer by network analysis |
| Q37610084 | Neem leaf extract inhibits mammary carcinogenesis by altering cell proliferation, apoptosis, and angiogenesis |
| Q37116576 | PTEN loss mediated Akt activation promotes prostate tumor growth and metastasis via CXCL12/CXCR4 signaling |
| Q39424549 | Prostate Cancer Stem Cell Markers Drive Progression, Therapeutic Resistance, and Bone Metastasis |
| Q34302881 | Single-cell genetic analysis reveals insights into clonal development of prostate cancers and indicates loss of PTEN as a marker of poor prognosis. |
| Q39150840 | Stable expression of human VDR in murine VDR-null cells recapitulates vitamin D mediated anti-cancer signaling. |
| Q34393461 | Targeting the PDGF signaling pathway in tumor treatment |
| Q38806364 | The interaction between androgen receptor and PDGF-D in the radiation response of prostate carcinoma. |
| Q37615017 | The osteoblastic and osteoclastic interactions in spinal metastases secondary to prostate cancer |
| Q38160946 | Therapeutic targeting of platelet-derived growth factor receptors in solid tumors |
Search more.